The French NITAG integrates the vaccine FLUCELVAX in the influenza strategy for the use in children from 6 months with risk factors.
In France, seasonal influenza vaccination is recommended every year to people aged 65 and over, to people at risk of severe or complicated influenza, caregivers and children from the age of 6 months with risk factors of serious form. Infants without co-morbidity of at least 24 months may also benefit from vaccination, with the influenza vaccines indicated for this age group. In April 2025, the FLUCELVAX vaccine received an extension of indication in children from 6 months. According to the laboratory, the population of children aged 6 to 23 months at risk, to be vaccinated, is of the order of 290 000 each year. Previous work by the HAS has made it possible to establish the vaccination strategy for children from 2 years. The HAS today publishes the opinion on the evaluation of the relevance of integrating FLUCELVAX into the influenza vaccine strategy in children from 6 months, following the extension of its indication.
